Leonard Zehr, Author at BioTuesdays

Feature

9 Meters Biopharma targeting rare and unmet needs in GI disorders

By Leonard Zehr 9 Meters Biopharma (NASDAQ: NMTR) expects to report clinical trial data readouts in 2021 from two gastrointestinal disorders: short bowel syndrome, an underserved and debilitating rare disease, and...

October 27, 2020

Feature

Monopar Therapeutics readies two key clinical trials in fourth quarter

Monopar Therapeutics (NASDAQ:MNPR), which focuses on developing cancer therapies and treatments for cancer-related adverse events, is on track for two important clinical trials with its lead drug candidates, Validive...

October 6, 2020

Feature

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Feature

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

Closely-held PregnanTech is completing a clinical safety study with its Lioness device to prevent preterm birth in non-pregnant women about to undergo a hysterectomy as a steppingstone to a larger proof-of-concept study...

September 22, 2020

Feature

BioCardia developing autologous and allogenic cardiovascular cell therapies

BioCardia (NASDAQ:BCDA) is developing two late-stage clinical autologous cell therapies, known as CardiAMP, for ischemic heart failure and chronic myocardial ischemia, a neurokinin 1 receptor positive (NK1R+) allogenic...

September 15, 2020

Feature

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

By Leonard Zehr The University Hospital of Cologne is one of the largest in Germany with 59 departments and institutions, and is a leading interdisciplinary Oncology Center of Excellence. Recently, the interdisciplinary...

September 8, 2020

Feature

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

As the founder of Atlanta’s renowned Busch Center, Dr. Joseph Busch Jr. brings a 40-year-plus track record in diagnostic radiology and hundreds of international research studies to preventative screening and accurate...

August 11, 2020

Feature

Prothena building diverse pipeline in multiple neurodegenerative and rare indications

Fueled by decades of research in protein dysregulation and fundamental neuroscience, Prothena (NASDAQ:PRTA) is advancing a pipeline of therapeutic candidates with the potential to change the course of diseases such as...

August 4, 2020

Feature

InspireMD advancing global distribution of CGuard EPS carotid stent for stroke prevention; gearing for U.S. pivotal trial

InspireMD (NYSE American:NSPR) is awaiting a decision from the FDA for an investigational device exemption as a steppingstone for a pivotal trial of its CE Mark-approved CGuard Carotid Stent System for the prevention of...

July 28, 2020

Feature

Soliton seeking FDA okay to treat cellulite with Rapid Acoustic Pulse

Soliton (NASDAQ:SOLY) has filed a 510(k) submission for FDA clearance of its Rapid Acoustic Pulse (RAP) technology for reduction in the appearance of cellulite, which affects between 80% and 90% of women. The FDA has...

July 21, 2020

Author - Leonard Zehr

9 Meters Biopharma targeting rare and unmet needs in GI disorders

Monopar Therapeutics readies two key clinical trials in fourth quarter

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

BioCardia developing autologous and allogenic cardiovascular cell therapies

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

Prothena building diverse pipeline in multiple neurodegenerative and rare indications

InspireMD advancing global distribution of CGuard EPS carotid stent for stroke prevention; gearing for U.S. pivotal trial

Soliton seeking FDA okay to treat cellulite with Rapid Acoustic Pulse

Subscribe